CombiMatrix gains $2.2m US funding:
This article was originally published in Clinica
The US Department of Defense (DoD) has awarded a one-year, $2.2m contract to CombiMatrix to fund the further development of its microarrays for a multipathogen- and chemical-detection system, using its "on chip" electrochemical detection process. The Newport Beach, California company has demonstrated that its products can simultaneously detect toxins, viruses and bacteria using its semiconductor-based microarrays, under previously DoD-funded research programmes. These systems are currently in use at several military and government laboratories as well as civilian installations.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.